Page 441 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses (continued)
Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Adherence to
AS/WW
Carter 176 clinical DOD CPDR 1991- 313 ≤70 yr, Not Multivariable 1. T2c vs. T1a/b HR 16.4 (CI 3.16,
2003 database 2002 Gleason ≤6 explicitly Cox 85.16), P=0.0009
14581423 (no pattern 4), provided proportional 2. PSA doubling time 2-5 yr vs. <2
≤3 positive hazard yr HR 0.32 (CI 0.20, 0.52),
cores, ≤T2, predicts P<0.0001
PSA ≤ 20 definitive 2º Median f/u 3.8 yr
treatment
ng/mL NS: age; PSA at dx; Gleason,
race; FH; comorbidities
Latini 164 Clinical, CaPSURE 1997- 105 Patients with No Cox PSA velocity, ng/ml/yr,
2007 social, 2002 biopsy-proven treatment proportional - -0.51-0.50 vs. <0.51, HR=0.402
17632144 delivery localized for ≥6 mo hazards (CI 0.092, 1.754); P=0.23
system prostate after dx regression - 0.51-1.50 vs. <-0.51, HR=1.518
cancer, who time-to-active (CI 0.425, 5.419); P=0.52
elected AS. treatment/ - ≥1.51 vs. <-0.51, HR=3.181 (CI
AS 1.122, 9.016); P=0.03
interruption P=0.01
Cancer anxiety change rate,
HR=1.019 (CI 1.004, 1.035);
P=0.01

The following NS variables were
also considered in the model (HR
estimates not provided):
relationship; clinical risk group,
D’Amico classification; BMI ; race;
education; number of
comorbidities; insurance; age at
dx; PSA velocity x CA change rate
(interaction).

C-138